covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | October 14, 2020 | News story | Research and Development COVID-19, coronavirus, covid news, pandemic, weekly roundup 

The COVID-19 news this week focuses on FDA authorisations, with Eli Lilly seeking Emergency Use Authorization (EUA) from the FDA for its antibody therapy after releasing interim data based on early trial results, while Regeneron has announced that it has applied for an EUA for its own experimental antibody therapy that had been given to President Trump in his fight against coronavirus.

In other news, Tedros Adhanom Ghebreyesus, Director of the World Health Organization, has warned against pursuing a strategy of herd immunity to fight national COVID-19 outbreaks and newly released data has revealed that coronavirus has resulted in many more deaths than influenza or pneumonia in England and Wales throughout 2020.

1. GSK tells UK staff to turn off NHS COVID-19 tracking app while at workPublished 07/10/20

GlaxoSmithKline has told its employees to turn off the new NHS coronavirus tracking app at work as it could be disruptive to its business, according to The Guardian.

2. Head of WHO says herd immunity strategies for COVID-19 are ‘unethical’Published 13/10/20

Tedros Adhanom Ghebreyesus, Director of the World Health Organization, has warned against pursuing a strategy of herd immunity to fight national COVID-19 outbreaks.

3. Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisationsPublished 08/10/20

Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.

4. COVID-19 has caused over three times more deaths than flu or pneumonia in England and WalesPublished on 08/10/20

Newly released data has revealed that COVID-19 has resulted in many more deaths than influenza or pneumonia in England and Wales throughout 2020, it has been reported.

5. Regeneron applies for FDA Emergency Use Authorization for COVID-19 antibody treatment given to TrumpPublished 08/10/20

Regeneron has announced that it has applied for an Emergency Use Authorization from the FDA for its experimental antibody therapy that has been given to President Trump in his fight against coronavirus.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content